Decibel Therapeutics Expands Leadership Team With World-Class Bioinformatics Scientist; Appoints Three New Members to its Board of Directors

Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease

CytomX to Present at the 35th Annual J.P. Morgan Healthcare Conference

UPDATE: CytomX Announces Time Change for its Presentation at the 35th Annual J.P. Morgan Healthcare Conference

Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference

Foundation Medicine Reports Preliminary 2016 Results

Agios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017

Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference

TARIS Biomedical® Announces Positive Results from Ph1b Trial of TAR-200 (GemRIS™) in Patients with Muscle Invasive Bladder Cancer

Allena Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

Neon Therapeutics Secures $70 Million in Series B Financing

Pliant Therapeutics Appoints Leading Academic Researcher and Industry Veteran Rik Derynck, Ph.D. As Scientific Founder

Voyager Therapeutics Elects Wendy Dixon, Ph.D. and Glenn Pierce, M.D., Ph.D. to Board of Directors

Editas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference

bluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference

Agios to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017

Agios Appoints Ian Clark to Board of Directors

Foundation Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference

Global Blood Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

MyoKardia Announces Advancement to Next Phase of Global Collaboration with Sanofi

Voyager Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer

Sage Therapeutics to Participate in Goldman Sachs Healthcare Conference

Neon Therapeutics to Present at 35th Annual J.P. Morgan Healthcare Conference

REVOLUTION Medicines Raises Additional $25 Million in Series A Financing

Foundation Medicine Receives FDA Approval of FoundationFocusâ„¢ CDxBRCA as a Companion Diagnostic for Rubracaâ„¢ (rucaparib) for the Treatment of Women with Ovarian Cancer

Editas Medicine Extends CRISPR Genome Editing Leadership Through Licensing of New CRISPR Technologies

Sage Therapeutics Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Mood Disorders

Global Blood Therapeutics Added to NASDAQ Biotechnology Index

Agios Provides Update on PKR Program

bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement

Third Rock Ventures launches Goldfinch Bio with $55M in Series A funding to bring precision medicine to patients with kidney disease

bluebird bio Announces First Patient Treated with LentiGlobin Drug Product in Northstar-2 (HGB-207) Phase 3 Trial of Patients with Transfusion-Dependent β-Thalassemia

CytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072

CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration

REVOLUTION Medicines Names Distinguished Cancer Scientists and Drug Hunters to Senior Advisory Roles

Voyager Therapeutics to Attend Upcoming Investor Conference

MyoKardia to Present at 2016 BMO Capital Markets Healthcare Conference

Sage Therapeutics to Webcast R&D Day on December 13, 2016

Voyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease

Fulcrum Therapeutics Appoints Renowned Experts in CNS Disorders and Muscular Dystrophies to Serve on Newly Formed Scientific Advisory Board

Nurix Appoints Robert Tjian, Ph.D. of The Column Group to its Board of Directors

Sage Announces Expedited Development Plan for SAGE-547 in the Treatment of Postpartum Depression based on FDA Breakthrough Therapy Meeting

Agios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies

bluebird bio Provides Updates on HSC Gene Therapy Programs

CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration

Global Blood Therapeutics Announces New Details on its Novel Patient Reported Outcomes (PRO) Tool to be used in Phase 3 HOPE Study

Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis

Agios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency

Global Blood Therapeutics Announces New Long-Term Clinical Data from Ongoing Phase 1/2 Trial of GBT440 in Sickle Cell Disease at ASH

bluebird bio Presents New Data from HGB-205 Study of LentiGlobin™ Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting